. 2022 Feb 7;2(1):1–8. doi: 10.1530/EO-21-0021
This work is licensed under a Table 1.
Clinical characteristics of the entire cohort of patients with ACC (n = 45) and patient subgroup with a complete lipid profile before and after the introduction of mitotane (n = 26). Data for continuous variables are expressed as median ± s.d. Categorical variables are expressed as frequency (n (%)).
| Variables | n= 26 | n= 45 |
|---|---|---|
| Age (years) | 50 ± 13 | 50 ± 14 |
| Sex | ||
| Male | 6 (23%) | 10 (22%) |
| Female | 20 (77%) | 35 (78%) |
| ENSAT stage | ||
| I | 0 (0%) | 2 (4%) |
| II | 9 (35%) | 11 (24%) |
| III | 11 (42%) | 15 (33%) |
| IV | 6 (23%) | 17 (38%) |
| Median tumor diameter (cm) | 11,58 (2.5–21.5) | 11,38 (2.5–24) |
| Median Weiss score | 6 (n = 16) (3–9) | 6 (n = 26) (3–9) |
| Functional status | ||
| Secreting tumors | 16 (62%) | 29 (64%) |
|
5 3 2 6 |
10 4 2 13 |
| Non-secreting tumors | 3 (11%) | 5 (11%) |
| Unknown | 7 (27%) | 11 (25%) |
| Concomitant treatments | ||
| Cytotoxic chemotherapy | 9 (35%) | 20 (44%) |
| Past medical history of treated dyslipidemia | ||
| Yes | 6 (23%) | 10 (22%) |
| No | 20 (77%) | 34 (76%) |